Skip to main content
Premium Trial:

Request an Annual Quote

Wyeth Using Singulex's Erenna Biomarker-Detection System

NEW YORK (GenomeWeb News) - Singulex said today that it has installed its Erenna biomarker-detection platform in Wyeth Research’s labs under its Erenna Technology Access Program.
The ETAP program includes the Erenna, which is used to detect and count single molecules, as well as customized immunoassay development services, reagents and software and other services. Singulex is working with Wyeth to develop immunoassays on the platform to accurately measure specific biomarkers in human blood.
Erenna is capable of measuring low levels and small changes of protein biomarkers in a variety of biological samples, the company said.
Wyeth is currently using Erenna to validate several assays “that should help us guide our clinical programs, said Ole Vesterqvist, senior director of Wyeth’s Biomarker Laboratory in Clinical Translational Medicine, in a statement.
Financial terms of the agreement were not released.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.